| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Sarcosine-d3 targets the same biological systems as unlabeled sarcosine. Sarcosine is an endogenous amino acid that is a competitive inhibitor of glycine transporter type I (GlyT1) and a glycine receptor co-agonist. By inhibiting GlyT1, sarcosine increases glycine concentrations, enhancing NMDA receptor function. The deuterated compound is primarily used as an analytical tool for studying sarcosine metabolism.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, Sarcosine-d3 is used as an internal standard and in metabolic studies. Sarcosine displays antipsychotic activity and has the potential to treat schizophrenia. It potentiates the action of glycine on the NMDA glycine binding site. The deuterated compound is used to trace sarcosine metabolism and to study its biochemical pathways. |
| ln Vivo |
In vivo, Sarcosine-d3 is not used as a therapeutic agent but as a research tool for metabolic studies. The deuterated label allows for the tracing of sarcosine in biological systems using mass spectrometry or NMR. Its in vivo effects are minimal at tracer doses.
|
| Enzyme Assay |
The in vitro assays for Sarcosine-d3 typically involve metabolic studies using LC-MS/MS or NMR. The compound is added to biological samples (e.g., plasma, urine, cell lysates) as an internal standard. For GlyT1 inhibition studies, cells expressing GlyT1 are treated with sarcosine, and glycine uptake is measured using radiolabeled glycine.
|
| Cell Assay |
For in vitro cellular assays, Sarcosine-d3 may be used in cell culture studies to track sarcosine metabolism. Cells are treated with the compound, and the media and cell lysates are analyzed by LC-MS/MS. The deuterated compound allows for precise quantification and metabolic tracing.
|
| Animal Protocol |
For in vivo studies, Sarcosine-d3 is typically administered to animals via oral or intravenous administration at tracer doses. Blood samples are collected at various time points, and concentrations of the labeled compound are measured by LC-MS/MS. Pharmacokinetic parameters are calculated from the concentration-time profiles.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Sarcosine-d3 are expected to be similar to those of unlabeled sarcosine. Sarcosine is absorbed and distributed similarly to other amino acids. The deuterated compound is used as a tracer to study sarcosine pharmacokinetics.
|
| Toxicity/Toxicokinetics |
Toxicology data for Sarcosine-d3 are limited, as the compound is used at tracer doses. At the low doses used for analytical purposes, the compound is considered safe and non-toxic.
|
| References |
|
| Additional Infomation |
Sarcosine-d3 (methyl-d3) is a deuterium-labeled form of Sarcosine (N-Methylglycine), an endogenous amino acid. It has a molecular formula of C3H4D3NO2 and a molecular weight of 92.11. Sarcosine is a competitive GlyT1 inhibitor and glycine receptor co-agonist. Sarcosine-d3 is used in mass spectrometry and NMR spectroscopy to investigate sarcosine's biochemical pathways.
|
| Molecular Formula |
C3H4D3NO2
|
|---|---|
| Molecular Weight |
92.11166
|
| Exact Mass |
92.066
|
| CAS # |
118685-91-9
|
| Related CAS # |
Sarcosine;107-97-1
|
| PubChem CID |
16213596
|
| Appearance |
Colorless to off-white ointment
|
| Density |
1.13g/cm3
|
| Boiling Point |
195.1ºC at 760 mmHg
|
| Melting Point |
208ºC (dec.)(lit.)
|
| Flash Point |
71.8ºC
|
| Vapour Pressure |
0.184mmHg at 25°C
|
| Index of Refraction |
1.431
|
| LogP |
-2.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
6
|
| Complexity |
52.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(CNC([2H])([2H])[2H])=O
|
| InChi Key |
FSYKKLYZXJSNPZ-FIBGUPNXSA-N
|
| InChi Code |
InChI=1S/C3H7NO2/c1-4-2-3(5)6/h4H,2H2,1H3,(H,5,6)/i1D3
|
| Chemical Name |
2-(trideuteriomethylamino)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~1357.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.8566 mL | 54.2829 mL | 108.5658 mL | |
| 5 mM | 2.1713 mL | 10.8566 mL | 21.7132 mL | |
| 10 mM | 1.0857 mL | 5.4283 mL | 10.8566 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
